Ignite Creation Date:
2025-12-24 @ 6:44 PM
Ignite Modification Date:
2026-04-23 @ 12:06 AM
Study NCT ID:
NCT02985957
Status:
COMPLETED
Last Update Posted:
2025-12-22
First Post:
2016-11-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-26
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-01-07
Completion Date Type:
ACTUAL
First Submit Date:
2016-11-22
First Submit QC Date:
None
Study First Post Date:
2016-12-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-03-30
Results First Submit QC Date:
None
Results First Post Date:
2023-04-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-19
Last Update Post Date:
2025-12-22
Last Update Post Date Type:
ESTIMATED